The Department of Veterans Affairs said on August 13, 2026 that it has secured a record $10.44 billion in pharmaceutical price reductions so far in fiscal year 2026, the largest amount the agency has ever reported and nearly double what it achieved during the final year of the Biden administration. The savings come from the same federal pricing authority VA has used for decades to negotiate what it pays for the medications it dispenses to veterans, a population that skews older and relies heavily on maintenance prescriptions.
Three Years of Widening Discounts
VA’s own numbers show a steady climb. The agency achieved $5.23 billion in pharmaceutical price reductions in fiscal year 2024, then $7.99 billion in fiscal year 2025, and is now reporting $10.44 billion for fiscal year 2026 with weeks still remaining before the fiscal year closes at the end of September, according to the department’s own press release. That means the current fiscal year’s total could still grow before final numbers are tallied.
“Under President Trump, VA is racking up huge wins for Veterans and taxpayers by demanding a better deal from pharmaceutical companies,” VA Secretary Doug Collins said in the release announcing the figures. The department credited a “major effort” launched during the current administration to secure lower prices on the medications it uses most often to treat veterans, particularly newer therapies that tend to carry higher prices early in their life on the market.
Free retirement updates: Enrollment and claim windows come and go, and missing one can cost real money. The free Retirement Shield newsletter keeps readers ahead of the deadlines that matter. Sign up free.
How VA Negotiates Prices Drug Companies Cannot Refuse
VA’s leverage does not come from goodwill on the part of drug manufacturers. Under federal law, companies that want their outpatient drugs covered by Medicaid must also make those same drugs available to VA, the Defense Department and other federal health programs at a discounted rate known as the Federal Ceiling Price. That price is required by statute to sit at least 24 percent below a drug’s non-federal average manufacturer price, and manufacturers report the underlying pricing data directly to VA’s National Acquisition Center, according to the department’s own pharmaceutical pricing page. That framework is described in more detail in a Congressional Research Service comparison of VA, Medicaid and Medicare drug pricing policies. A manufacturer that refuses to sign the required Pharmaceutical Pricing Agreement loses eligibility for Medicaid to cover its outpatient drugs anywhere in the country, which is the leverage that makes the Federal Ceiling Price effectively mandatory rather than voluntary.
That 24 percent statutory floor has not changed in decades, but VA’s $10.44 billion figure reflects negotiations that go beyond it. The department separately negotiates additional discounts through its Pharmaceutical Pricing Agreements and Federal Supply Schedule contracts, which is how the total climbed from $5.23 billion in savings just two fiscal years ago to more than double that amount now.
What the Extra Savings Are Funding
VA tied the pricing announcement to a broader list of gains it says veterans have seen recently. The department said it enrolled more than 215,000 new veterans in VA healthcare so far in 2026, opened 40 new VA healthcare facilities since January 20, 2025, and completed a record 82,083,918 direct-care appointments in fiscal year 2025, up 4.1 percent from the year before. It also said the backlog of veterans waiting on benefits decisions has fallen more than 70 percent since January 20, 2025, after growing during the prior administration. The department also said it completed a record 59,989,662 community care appointments in fiscal year 2025, up 12 percent from the prior year, and permanently housed 51,936 homeless veterans during the same fiscal year, the highest total in seven years, according to the same press release.
Lower drug costs do not by themselves pay for new clinics or shorten a benefits backlog, but VA’s own framing ties the pharmaceutical savings directly to its capacity to treat more veterans, particularly as newer and more expensive therapies enter the market. Whether the fiscal year 2026 total holds at $10.44 billion or climbs further will not be clear until VA closes the books after September 30, 2026.
Why This Matters at the Pharmacy Counter
Many veterans who rely on VA for prescriptions are also Medicare-eligible retirees who could fill the same prescription through Medicare Part D instead. VA’s own pricing typically runs below what a private Part D plan pays for the same drug, in part because of the Federal Ceiling Price described above, which is one reason many veterans choose VA pharmacy benefits over an outside Medicare plan for their maintenance medications. A larger discount pool does not change a veteran’s copay directly, since VA copays are set separately by law, but it does support VA’s ability to keep formulary access broad rather than restricting which drugs are covered.
VA has not said whether the fiscal year 2026 savings will translate into any specific new benefit or coverage change, and the August 13 announcement did not include such a commitment. The figures stand, for now, as a measure of negotiating leverage rather than a promise of new services, with the final fiscal year 2026 number due once VA’s books close in October.
This article was produced with AI assistance and reviewed by The Financial Wire editorial team.
More Financial Reading
- What really happens to your joint savings account when you die?
- The ideal retirement withdrawal rate so your savings actually last
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
